<DOC>
	<DOC>NCT01332097</DOC>
	<brief_summary>This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.</brief_summary>
	<brief_title>Safety &amp; Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients with COPD (Stage II to IV) with a COPD exacerbation. Smoking history of 10 pack years. Females must not be of childbearing potential. Use of steroids in the last 30 days or calcium channel blockers in the last 48 hours. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Exacerbation</keyword>
	<keyword>Pulmonary Inflammation</keyword>
</DOC>